ImageneBio (IMA) Cash from Operations (2020 - 2025)

ImageneBio has disclosed Cash from Operations across 6 years of filings, most recently posting -$21.5 million for Q3 2025.

• In Q3 2025, Cash from Operations fell 265.83% year-over-year to -$21.5 million; the TTM figure through Sep 2025 stood at -$68.8 million (down 73.43% YoY), while the FY2024 annual figure was -$46.0 million, up 42.31% from the prior year.
• Cash from Operations came in at -$21.5 million for Q3 2025 at ImageneBio, down from -$11.9 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $13.0 million in Q3 2024 to a low of -$28.2 million in Q4 2024.
• Average Cash from Operations over 5 years is -$15.8 million, with a median of -$18.0 million recorded in 2021.
• Year-over-year, Cash from Operations jumped 164.82% in 2024 and plunged 265.83% in 2025.
• Over 5 years, Cash from Operations stood at -$13.4 million in 2021, then sank by 32.07% to -$17.7 million in 2022, then fell by 23.59% to -$21.8 million in 2023, then fell by 29.06% to -$28.2 million in 2024, then rose by 23.67% to -$21.5 million in 2025.
• Per Business Quant data, the three most recent Cash from Operations figures were -$21.5 million in Q3 2025, -$11.9 million in Q2 2025, and -$7.2 million in Q1 2025.